Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Hermann Brenner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6129-1572; OpenAlex author ID A5077206620. Sources: OpenAlex.

Their work

Papers
35 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2015: 3 papers · 2016: 3 papers · 2017: none · 2018: 5 papers · 2019: 4 papers · 2020: 1 paper · 2021: 7 papers · 2022: 1 paper · 2023: 5 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 35

  1. Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2026.1192↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  4. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  5. Overcoming underestimation of the association of excess weight with pancreatic cancer due to prediagnostic weight loss: Umbrella review of systematic reviews, … Last author DOI 10.1111/obr.13799↗
  6. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  7. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  8. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  9. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  10. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  11. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  12. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  13. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  14. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  15. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large Internat… Last author DOI 10.1097/sla.0000000000003558↗
  16. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  17. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  18. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  19. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  20. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  21. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  22. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  23. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Last author DOI 10.1136/gutjnl-2017-314828↗
  24. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a … Co-author DOI 10.1186/s12916-019-1304-y↗
  25. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  26. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. Last author DOI 10.1002/ijc.31628↗
  27. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  28. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international populati… Last author DOI 10.1186/s12916-018-1120-9↗
  29. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among… Last author DOI 10.2147/clep.s160973↗
  30. Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. Last author DOI 10.1097/mpa.0000000000000588↗
  31. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  32. A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection. Last author DOI 10.18632/oncotarget.7098↗
  33. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  34. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCAR… Co-author DOI 10.1016/j.ejca.2015.07.034↗
  35. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Hoffmeister · 2 shared papers, 2024–2026 · strength 0.61
  2. Lina Jansen · 7 shared papers, 2016–2021 · strength 0.54
  3. Lydia G. van der Geest · 6 shared papers, 2018–2021 · strength 0.49
  4. V.E.P.P. Lemmens · 5 shared papers, 2018–2021 · strength 0.40
  5. Lei Huang · 5 shared papers, 2018–2021 · strength 0.40
  6. Jie Ding · 1 shared paper, 2026 · strength 0.36
  7. Marc G. Besselink · 4 shared papers, 2018–2021 · strength 0.33
  8. Robert Grützmann · 3 shared papers, 2019–2021 · strength 0.26
  9. Marko Mandic · 1 shared paper, 2024 · strength 0.26
  10. Federico Canzian · 2 shared papers, 2022–2023 · strength 0.20
  11. Giulia Martina Cavestro · 2 shared papers, 2022–2023 · strength 0.20
  12. Rita Teresa Lawlor · 2 shared papers, 2022–2023 · strength 0.20
  13. Lívia Archibugi · 2 shared papers, 2022–2023 · strength 0.20
  14. John P. Neoptolemos · 2 shared papers, 2022–2023 · strength 0.20
  15. Gabriele Capurso · 2 shared papers, 2022–2023 · strength 0.20
  16. Daniele Campa · 2 shared papers, 2022–2023 · strength 0.20
  17. Giuseppe Vanella · 2 shared papers, 2022–2023 · strength 0.20
  18. Francesca Tavano · 2 shared papers, 2022–2023 · strength 0.20
  19. Luca Morelli · 2 shared papers, 2022–2023 · strength 0.20
  20. Manuel Gentiluomo · 2 shared papers, 2022–2023 · strength 0.20
  21. Jakob Robert Izbicki · 2 shared papers, 2022–2023 · strength 0.20
  22. Casper H.J. van Eijck · 2 shared papers, 2022–2023 · strength 0.20
  23. Pavel Souček · 2 shared papers, 2022–2023 · strength 0.20
  24. Raffaele Pezzilli · 2 shared papers, 2022–2023 · strength 0.20
  25. Daniela Basso · 2 shared papers, 2022–2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.